Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes.

Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Paparizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M; Collaboration of Observational HIV Epidemiological Research Europe.

Blood. 2011 Jun 9;117(23):6100-8. doi: 10.1182/blood-2010-08-301531. Epub 2011 Mar 2.

2.

Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy.

Gotti D, Danesi M, Calabresi A, Ferraresi A, Albini L, Donato F, Castelli F, Scalzini A, Quiros-Roldan E; Brescia HIV Cancer Study Group.

AIDS Patient Care STDS. 2013 May;27(5):259-65. doi: 10.1089/apc.2012.0424. Epub 2013 Apr 21.

PMID:
23600703
3.

Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma.

Kowalkowski MA, Mims MP, Amiran ES, Lulla P, Chiao EY.

PLoS One. 2013 Oct 2;8(10):e77409. doi: 10.1371/journal.pone.0077409. eCollection 2013.

4.

HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.

Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V, Partisani M, Poizot-Martin I, Rouveix E, Engels EA, Costagliola D, Goedert JJ; FHDH-ANRS CO4.

Blood. 2011 Jul 7;118(1):44-9. doi: 10.1182/blood-2011-02-339275. Epub 2011 May 6.

5.

A declining CD4 count and diagnosis of HIV-associated Hodgkin lymphoma: do prior clinical symptoms and laboratory abnormalities aid diagnosis?

Gupta RK, Marks M, Edwards SG, Smith K, Fletcher K, Lee SM, Ramsay A, Copas AJ, Miller RF.

PLoS One. 2014 Feb 4;9(2):e87442. doi: 10.1371/journal.pone.0087442. eCollection 2014.

6.

Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan.

Yotsumoto M, Hagiwara S, Ajisawa A, Tanuma J, Uehira T, Nagai H, Fujikawa Y, Maeda S, Kitano K, Arima N, Uno K, Iwai T, Hongo I, Ota Y, Fukutake K, Okada S.

Int J Hematol. 2012 Aug;96(2):247-53. doi: 10.1007/s12185-012-1127-5. Epub 2012 Jul 1.

PMID:
22752537
7.

Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.

Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Chene G, Egger M.

Antivir Ther. 2009;14(8):1065-74. doi: 10.3851/IMP1462.

8.

CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma.

Hoffmann C, Schommers P, Wolf E, Müller M, Schultze A, Krznaric I, Stoehr A, Wolf T, Fäktenheuer G, Stier B, Wyen C, Hentrich M.

AIDS. 2016 Mar 13;30(5):753-60. doi: 10.1097/QAD.0000000000000980.

PMID:
26605513
9.

Managing HIV and Hodgkin lymphoma in the twenty-first century.

Aries J, Montoto S.

Curr Hematol Malig Rep. 2014 Sep;9(3):227-32. doi: 10.1007/s11899-014-0215-4.

PMID:
24906351
10.

High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.

Besson C, Lancar R, Prevot S, Brice P, Meyohas MC, Marchou B, Gabarre J, Bonnet F, Goujard C, Lambotte O, Boué F, Mounier N, Partisani M, Raffi F, Costello R, Hendel-Chavez H, Algarte-Genin M, Trabelsi S, Marchand L, Raphael M, Taoufik Y, Costagliola D.

Clin Infect Dis. 2015 Nov 1;61(9):1469-75. doi: 10.1093/cid/civ627. Epub 2015 Jul 29.

PMID:
26223997
11.

Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.

Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, Parruti G, Galli M, Gori A, Monforte Ad; ICONA Foundation Study.

AIDS. 2013 Mar 13;27(5):769-79. doi: 10.1097/QAD.0b013e32835cb747.

PMID:
23719349
12.

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Lundgren JD; Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD.

Clin Infect Dis. 2013 Oct;57(7):1038-47. doi: 10.1093/cid/cit423. Epub 2013 Aug 6.

PMID:
23921881
13.

Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans.

Kowalkowski MA, Mims MA, Day RS, Du XL, Chan W, Chiao EY.

Cancer Epidemiol. 2014 Aug;38(4):386-92. doi: 10.1016/j.canep.2014.05.009. Epub 2014 Jun 16.

14.

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.

Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D; Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort.

Lancet Oncol. 2009 Dec;10(12):1152-9. doi: 10.1016/S1470-2045(09)70282-7. Epub 2009 Oct 7.

PMID:
19818686
15.

Antiretroviral therapy initiation in an Australian cohort: implications for increased use of antiretroviral therapy.

Stratov I, Kent SJ.

Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):253-9. doi: 10.1007/s10096-014-2227-3. Epub 2014 Aug 20.

PMID:
25139203
16.

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.

Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JD; EuroSIDA study group.

Lancet. 2007 Aug 4;370(9585):407-13.

PMID:
17659333
17.

Hodgkin lymphoma in the Swiss HIV Cohort Study.

Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, Bohlius J, Boffi El Amari E, Karrer U, Jundt G, Bordoni A, Ess S, Franceschi S; Swiss HIV Cohort Study.

Blood. 2009 Jun 4;113(23):5737-42. doi: 10.1182/blood-2009-02-204172. Epub 2009 Mar 31.

18.

Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.

Mary-Krause M, Billaud E, Poizot-Martin I, Simon A, Dhiver C, Dupont C, Salmon D, Roudiere L, Costagliola D; Clinical Epidemiology Group of the French Hospital Database.

AIDS. 2006 Aug 1;20(12):1627-35.

PMID:
16868444
19.

Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective study.

Mutwa PR, Boer KR, Asiimwe-Kateera B, Tuyishimire D, Muganga N, Lange JM, van de Wijgert J, Asiimwe A, Reiss P, Geelen SP.

PLoS One. 2014 Nov 3;9(11):e111948. doi: 10.1371/journal.pone.0111948. eCollection 2014.

20.

Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS.

Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA.

Blood. 2006 Dec 1;108(12):3786-91. Epub 2006 Aug 17.

Supplemental Content

Support Center